The Covid-19 pandemic caused huge disruption for European biotech in 2020, but the industry pulled through. Let’s look back at some of the top moments in the last 12 months.
After the many drug approvals, startup foundations, and venture capital highs we saw in 2019, it looked like 2020 was going to be a comfortable year for the biotech industry in Europe. Instead, a pandemic threw the global economy into disarray; its impact will likely be felt for decades.
In spite of this unexpected challenge, the biotech sector has emerged stronger than ever this year. In fact, the pandemic has shone a spotlight on the industry, boosting interest in fields such as vaccines and infectious disease.
Some of the biotech areas that have emerged as winners this year include RNA therapeutics, gene therapy, and using artificial intelligence for drug discovery. In addition, companies developing meat alternative products have seen a surge in investments as the market expands, while immuno-oncology continues a fundraising glut year after year.
However, the situation hasn’t been great for the whole industry. Many small startups and nonprofit charities such as Cancer Research UK struggled to weather the pandemic chaos. A large number of biotechs grappled with clinical trial delays.
The post A Year to Remember: The Biggest European Biotech News in 2020 appeared first on Labiotech.eu.
Published on Mon, 28 Dec 2020 08:00:42 +0000 and made possible by power automate energy